Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pilar Peris

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Endocrine|October 21, 2010
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblastsAnna Enjuanes, Silvia Ruiz-Gaspà, Pilar Peris, et al.
The American Journal of Gastroenterology|October 24, 2003
Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosisNuria Guañabens, Albert Parés, Inmaculada Ros, et al.
Frontiers in Endocrinology|July 28, 2025
Risk factors for glucocorticoid induced osteoporosis in young adultsHelena Florez, Josep Lluis Carrasco, Martina Barberá, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
Hepatology (Baltimore, Md.)|August 13, 2011
Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseasesSilvia Ruiz-Gaspà, Angels Martinez-Ferrer, Nuria Guañabens, et al.
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|October 2, 2025
The Challenge of Hypophosphatasia Diagnosis in Patients with FibromyalgiaTamara L Rodríguez-Araya, Anastasia Mocritcaia, Eva González-Roca, et al.
Journal of Bone and Mineral Metabolism|April 27, 2004
Effect of hemodialysis and renal failure on serum biochemical markers of bone turnoverLuisa Alvarez, Jose-Vicente Torregrosa, Pilar Peris, et al.
Journal of Clinical Medicine|January 10, 2026
PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone DiseaseLaia Gifre, Maria Fusaro, Maria J Lloret, et al.
Rheumatology (Oxford, England)|October 20, 2019
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosisHelena Florez, José Hernández-Rodríguez, Africa Muxi, et al.
Endocrine|April 10, 2019
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatmentNúria Guañabens, María Jesús Moro-Álvarez, Enrique Casado, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Endocrine|October 21, 2010
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblastsAnna Enjuanes, Silvia Ruiz-Gaspà, Pilar Peris, et al.
The American Journal of Gastroenterology|October 24, 2003
Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosisNuria Guañabens, Albert Parés, Inmaculada Ros, et al.
Frontiers in Endocrinology|July 28, 2025
Risk factors for glucocorticoid induced osteoporosis in young adultsHelena Florez, Josep Lluis Carrasco, Martina Barberá, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
Hepatology (Baltimore, Md.)|August 13, 2011
Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseasesSilvia Ruiz-Gaspà, Angels Martinez-Ferrer, Nuria Guañabens, et al.
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre|October 2, 2025
The Challenge of Hypophosphatasia Diagnosis in Patients with FibromyalgiaTamara L Rodríguez-Araya, Anastasia Mocritcaia, Eva González-Roca, et al.
Journal of Bone and Mineral Metabolism|April 27, 2004
Effect of hemodialysis and renal failure on serum biochemical markers of bone turnoverLuisa Alvarez, Jose-Vicente Torregrosa, Pilar Peris, et al.
Journal of Clinical Medicine|January 10, 2026
PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone DiseaseLaia Gifre, Maria Fusaro, Maria J Lloret, et al.
Rheumatology (Oxford, England)|October 20, 2019
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosisHelena Florez, José Hernández-Rodríguez, Africa Muxi, et al.
Endocrine|April 10, 2019
The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatmentNúria Guañabens, María Jesús Moro-Álvarez, Enrique Casado, et al.
Pageof 9